No Data
J.P. Morgan Maintains ITeos Therapeutics(ITOS.US) With Buy Rating
J.P. Morgan analyst Brian Cheng maintains $ITeos Therapeutics(ITOS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 31.2% and a total average return of -18.7% over
We Think ITeos Therapeutics, Inc.'s (NASDAQ:ITOS) CEO Compensation Package Needs To Be Put Under A Microscope
Key Insights iTeos Therapeutics to hold its Annual General Meeting on 11th of June Total pay for CEO Michel Detheux includes US$578.9k salary The total compensation is 38% higher than the average
10 Health Care Stocks With Whale Alerts In Today's Session
This whale alert can help traders discover the next big trading opportunities.Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scan
ITeos Therapeutics (NASDAQ:ITOS): Harnessing the Power of Immunotherapy
Merck Discontinues Testing of Experimental Skin Cancer Combo Therapy
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.
ITeos Therapeutics Is Maintained at Buy by HC Wainwright & Co.